Literature DB >> 23062988

Implications of treatment that target protective mechanisms against diabetic nephropathy.

Akira Mima1, Weier Qi, George L King.   

Abstract

Diabetes results in vascular changes and dysfunction, and vascular complications are the leading cause of morbidity and mortality in diabetic patients. There has been a continual increase in the number of diabetic nephropathy patients and epidemic increases in the number of patients progressing to end-stage renal diseases. To identify targets for therapeutic intervention, most studies have focused on understanding how abnormal levels of glucose metabolites cause diabetic nephropathy, which is of paramount importance in devising strategies to combat the development and progression of diabetic nephropathy. However, less studied than the systemic toxic mechanisms, hyperglycemia and dyslipidemia might inhibit the endogenous vascular protective factors such as insulin, vascular endothelial growth factor, and platelet-derived growth factor. In this review, we highlight the importance of enhancing endogenous protective factors to prevent or delay diabetic nephropathy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23062988      PMCID: PMC3584697          DOI: 10.1016/j.semnephrol.2012.07.010

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  67 in total

1.  Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy.

Authors:  Mark E Williams; W Kline Bolton; Raja G Khalifah; Thorsten P Degenhardt; Robert J Schotzinger; Janet B McGill
Journal:  Am J Nephrol       Date:  2007-09-06       Impact factor: 3.754

2.  Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study.

Authors:  Hillary A Keenan; Tina Costacou; Jennifer K Sun; Alessandro Doria; Jerry Cavellerano; Joseph Coney; Trevor J Orchard; Lloyd Paul Aiello; George L King
Journal:  Diabetes Care       Date:  2007-05-16       Impact factor: 19.112

3.  Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension.

Authors:  Robert Wolk; William B Smith; Joel M Neutel; John Rubino; Dawei Xuan; James Mancuso; James Gilbert; Milton L Pressler
Journal:  Hypertension       Date:  2009-04-27       Impact factor: 10.190

4.  Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.

Authors:  Berend Isermann; Ilya A Vinnikov; Thati Madhusudhan; Stefanie Herzog; Muhammed Kashif; Janusch Blautzik; Marcus A F Corat; Martin Zeier; Erwin Blessing; Jun Oh; Bruce Gerlitz; David T Berg; Brian W Grinnell; Triantafyllos Chavakis; Charles T Esmon; Hartmut Weiler; Angelika Bierhaus; Peter P Nawroth
Journal:  Nat Med       Date:  2007-11-04       Impact factor: 53.440

5.  Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy.

Authors:  Pedro Geraldes; Junko Hiraoka-Yamamoto; Motonobu Matsumoto; Allen Clermont; Michael Leitges; Andre Marette; Lloyd P Aiello; Timothy S Kern; George L King
Journal:  Nat Med       Date:  2009-11-01       Impact factor: 53.440

6.  Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Authors:  Uzma F Mehdi; Beverley Adams-Huet; Philip Raskin; Gloria L Vega; Robert D Toto
Journal:  J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 10.121

7.  A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.

Authors:  Marvin Sinsakul; Mohammed Sika; Roger Rodby; John Middleton; Yu Shyr; Heidi Chen; Ernest Han; Ruediger Lehrich; Stephen Clyne; Gerald Schulman; Raymond Harris; Julia Lewis
Journal:  Am J Kidney Dis       Date:  2007-12       Impact factor: 8.860

8.  VEGF inhibition and renal thrombotic microangiopathy.

Authors:  Vera Eremina; J Ashley Jefferson; Jolanta Kowalewska; Howard Hochster; Mark Haas; Joseph Weisstuch; Catherine Richardson; Jeffrey B Kopp; M Golam Kabir; Peter H Backx; Hans-Peter Gerber; Napoleone Ferrara; Laura Barisoni; Charles E Alpers; Susan E Quaggin
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 9.  Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.

Authors:  Fuad N Ziyadeh
Journal:  Diabetes Res Clin Pract       Date:  2008-10-07       Impact factor: 5.602

10.  Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine.

Authors:  Sergei V Chetyrkin; Missy E Mathis; Amy-Joan L Ham; David L Hachey; Billy G Hudson; Paul A Voziyan
Journal:  Free Radic Biol Med       Date:  2007-10-04       Impact factor: 7.376

View more
  7 in total

Review 1.  A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.

Authors:  Akira Mima
Journal:  Adv Ther       Date:  2022-06-25       Impact factor: 4.070

2.  Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?

Authors:  Alessandro Doria; Monika A Niewczas; Paolo Fiorina
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

Review 3.  Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury.

Authors:  Selim Fakhruddin; Wael Alanazi; Keith E Jackson
Journal:  J Diabetes Res       Date:  2017-01-09       Impact factor: 4.011

Review 4.  Mitochondria in Diabetic Kidney Disease.

Authors:  Amna Ayesha Ahmad; Shayna Odeal Draves; Mariana Rosca
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

5.  Effects of pentoxifylline on proteinuria and glucose control in patients with type 2 diabetes: a prospective randomized double-blind multicenter study.

Authors:  Seung Jin Han; Hae Jin Kim; Dae Jung Kim; Seung Soo Sheen; Choon Hee Chung; Chul Woo Ahn; Se Hwa Kim; Yong-Wook Cho; Seok Won Park; Soo-Kyung Kim; Chul Sik Kim; Kyung Wook Kim; Kwan Woo Lee
Journal:  Diabetol Metab Syndr       Date:  2015-07-19       Impact factor: 3.320

Review 6.  Diabetic kidney disease: from epidemiology to clinical perspectives.

Authors:  Cheol Whee Park
Journal:  Diabetes Metab J       Date:  2014-08       Impact factor: 5.376

Review 7.  Incretin-Based Therapy for Prevention of Diabetic Vascular Complications.

Authors:  Akira Mima
Journal:  J Diabetes Res       Date:  2015-12-31       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.